Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCALIBER-Maintenance
NCT05827016Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Mar 2029
- Countries
- 34
01
Overview
A Phase 3 trial of iberdomide in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Started Jun 2023; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05827016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827016.